Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 14

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Small intestine neuroendocrine tumour

Recruiting

Efficacy of 177Lu-DOTATATE as Adjuvant Therapy After Surgery for Stage III Small Intestinal Neuroendocrine Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Oxodotreotide
  • Sponsor:Philipps-Universitaet Marburg

Colorectal cancer

Recruiting

Study of Telisotuzumab Adizutecan for Adults with Colorectal Cancer Who Have Positive Circulating Tumor DNA After Treatment but No Visible Cancer on Scans

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Adenocarcinoma pancreas+1

Recruiting

Evaluating 68Ga-FAPI-46 PET/CT Scanning for Improved Diagnosis in Patients with Pancreatic Cancer or Bile Duct Cancer Eligible for Curative Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Hyperinsulinaemic hypoglycaemia+2

Recruiting

Study on Ersodetug for Patients with Uncontrolled Low Blood Sugar Due to Tumor-Related High Insulin Levels

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anti-(Insulin Receptor) Human Monoclonal Antibody
  • Sponsor:Rezolute Inc.

Colorectal cancer metastatic

Recruiting

Study on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cystic fibrosis

Recruiting

Study on the Safety and Tolerability of Tamoxifen in Cystic Fibrosis Patients Not Eligible for CFTR Modulator Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Tamoxifen
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Adenocarcinoma gastric

Recruiting

Study of intraperitoneal chemotherapy (PIPAC) with cisplatin and doxorubicin combined with minimally invasive surgery in patients with high-risk gastric cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Odense University Hospital

Lactose intolerance

Recruiting

Study on the Effectiveness of Gaxilose for Diagnosing Lactose Intolerance in Children Aged 5 to 11 Years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:GAXILOSE
  • Sponsor:Venter Pharma S.L.

Colorectal cancer metastatic

Recruiting

Study on the Safety and Effectiveness of OMTX705 with Regorafenib and Tislelizumab for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:OMTX705
  • Sponsor:Oncomatryx Biopharma S.A.

Inflammatory bowel disease

Recruiting

Study on How Gut Bacteria Affect Energy Use in Cells for Healthy Adults and Patients with Inflammatory Bowel Disease Using Amphotericin B, Vancomycin, and Gentamicin Sulfate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:Amphotericin B
  • Sponsor:Assistance Publique Hopitaux De Paris

Colorectal cancer metastatic

Recruiting

Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Gastrointestinal carcinoma+4

Recruiting

Study on the Impact of Cisplatin and Drug Combination on Speech and Cognition in Cancer Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Capecitabine
  • Sponsor:Turku University Hospital

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.